cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Kiniksa Pharmaceuticals Ltd
3 own
7 watching
Current Price
$14.52
$0.06
(0.41%)
logo-knsa
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,009.49M
52-Week High
52-Week High
17.195
52-Week Low
52-Week Low
7.36
Average Volume
Average Volume
0.37M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,009.49M
icon52-Week High17.195
icon52-Week Low7.36
iconAverage Volume0.37M
iconDividend Yield--
iconP/E Ratio--
What does the Kiniksa Pharmaceuticals Ltd do?
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Read More
How much money does Kiniksa Pharmaceuticals Ltd make?
News & Events about Kiniksa Pharmaceuticals Ltd.
Globe Newswire
24days ago
ARCALYST (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively (unaudited) 2 of 3 cohorts enrolled in KPL-404 Phase 2 trial in rheumatoid arthritis; data expected in 1H 2024 Cash reserves expected to fund operations into at least 2025 HAMILTON...
Market News Video
4 months ago
In trading on Tuesday, shares of Kiniksa Pharmaceuticals Ltd (KNSA) crossed below their 200 day moving average of 10.67, changing hands as low as 10.24 per share. Kiniksa Pharmaceuticals Ltd shares are currently trading down about 5.2% on the day...
Globe Newswire
4 months ago
HAMILTON, Bermuda, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced the closing of the global license agreement ...
Frequently Asked Questions
Frequently Asked Questions
What is Kiniksa Pharmaceuticals Ltd share price today?
plus_minus_icon
Can Indians buy Kiniksa Pharmaceuticals Ltd shares?
plus_minus_icon
How can I buy Kiniksa Pharmaceuticals Ltd shares from India?
plus_minus_icon
Can Fractional shares of Kiniksa Pharmaceuticals Ltd be purchased?
plus_minus_icon
What are the documents required to start investing in Kiniksa Pharmaceuticals Ltd stocks?
plus_minus_icon
What is today’s traded volume of Kiniksa Pharmaceuticals Ltd?
plus_minus_icon
What is today’s market capitalisation of Kiniksa Pharmaceuticals Ltd?
plus_minus_icon
What is the 52-Week High and Low Range of Kiniksa Pharmaceuticals Ltd?
plus_minus_icon
What percentage is Kiniksa Pharmaceuticals Ltd down from its 52-Week High?
plus_minus_icon
What percentage is Kiniksa Pharmaceuticals Ltd up from its 52-Week Low?
plus_minus_icon
Current Price
$14.52
$0.06
(0.41%)
logo-knsa
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00